RECRUITING

Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer

Talk to us

Conditions

Prostate Cancer

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This pilot clinical trial studies how well magnetic resonance spectroscopic imaging (MRSI) with hyperpolarized carbon 13 (13C) pyruvate alone or in combination with 13C 15N2 Urea works in finding prostate cancer that exhibits poorly differentiated or undifferentiated cells (high-grade) and that is restricted to the site of origin, without evidence of spread (localized) in patients undergoing radical prostatectomy. Diagnostic procedures, such as MRSI with hyperpolarized carbon (13C) pyruvate, may aid in the diagnosis of prostate cancer and in discriminating high-grade from low-grade prostate cancer and benign adjacent prostate tissue

Official Title

A Pilot Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) to Detect High Grade Localized Prostate Cancer

Quick Facts

Study Start:2016-03-22
Study Completion:2024-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02526368

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:MALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Biopsy-proven adenocarcinoma of the prostate; biopsy may be performed outside of University of California San Francisco (UCSF), if detailed results of sextant biopsy are available; a minimum of 20 patients out of a planned enrollment of 50 patients must have high-risk disease as defined by primary Gleason score of 4 or 5 on prior prostate biopsy
  2. * Planned radical prostatectomy at UCSF within 12 weeks following protocol MRI/MRSI
  3. * The subject is able and willing to comply with study procedures and provide signed and dated informed consent
  4. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  5. * Absolute neutrophil count (ANC) \>= 1500 cells/microliter (uL)
  6. * Hemoglobin \>= 9.0 mg/dL
  7. * Platelets \>= 75,000 cells/uL
  8. * Estimated creatinine clearance \>= 50 mL/min (by the Cockcroft Gault equation)
  9. * Bilirubin \< 1.5 x upper limit of normal (ULN) (unless Gilbert's is suspected)
  10. * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 1.5 x ULN
  1. * Patients who because of general medical or psychiatric condition or physiologic status cannot give valid informed consent
  2. * Patients unwilling or unable to undergo MR imaging, including patients with contra-indications to MRI, such as cardiac pacemakers or non-compatible intracranial vascular clips
  3. * Patients who cannot tolerate or have contra-indications to endorectal coil insertion; for example, patients with a prior abdominoperineal resection of the rectum or latex allergy
  4. * Patients with contra-indications to injection of gadolinium contrast; for example patients with prior documented allergy or those with inadequate renal function
  5. * Metallic hip implant or any other metallic implant or device that distorts local magnetic field and compromises the quality of MR imaging
  6. * Cryosurgery, surgery for prostate cancer, prostatic or pelvic radiotherapy prior to study enrollment; no limit on number of prior prostate biopsies; prior transurethral prostatic resection (TURP) is not allowed
  7. * Current or prior androgen deprivation therapy; a history of use of a 5-alpha reductase inhibitor is allowed, provided it was discontinued at least one month prior to study entry
  8. * Poorly controlled hypertension, with blood pressure at study entry \> 160/100; the addition of anti-hypertensives to control blood pressure is allowed for eligibility determination
  9. * Congestive heart failure or New York Heart Association (NYHA) status \>= 2
  10. * A history of clinically significant electrocardiography (EKG) abnormalities, including QT prolongation, a family history of prolonged QT interval syndrome, or myocardial infarction (MI) within 6 months of study entry; patients with rate-controlled atrial fibrillation/flutter will be allowed on study

Contacts and Locations

Study Contact

Louise Magat
CONTACT
(415) 502-1822
Louise.Magat@ucsf.edu

Principal Investigator

Ivan de Kouchkovsky, MD
PRINCIPAL_INVESTIGATOR
University of California, San Francisco

Study Locations (Sites)

University of California, San Francisco
San Francisco, California, 94143
United States

Collaborators and Investigators

Sponsor: Ivan de Kouchkovsky, MD

  • Ivan de Kouchkovsky, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2016-03-22
Study Completion Date2024-12-31

Study Record Updates

Study Start Date2016-03-22
Study Completion Date2024-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Prostate Cancer